Zai Lab
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Employees
- 2.1K
- Market Cap
- $1.9B
- Introduction
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.
Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema
Phase 2
Completed
- Conditions
- Eczema
- Interventions
- Drug: ZL-3101Drug: Placebo
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Zai Lab Pty. Ltd.
- Target Recruit Count
- 290
- Registration Number
- NCT03134352
- Locations
- 🇨🇳
Beijing Hospital of Traditional Chinese Medicine, Beijing, China
🇨🇳Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
🇨🇳Shanghai Dermatology Hospital, Shanghai, China
Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects
Phase 1
- Conditions
- Idiopathic Pulmonary FibrosisAsthmaChronic Obstructive Pulmonary Disease
- Interventions
- Drug: ZL-2102Drug: Placebo matching ZL-2102
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Zai Lab Pty. Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT02397005
- Locations
- 🇦🇺
Linear Clinical Research Unit, Perth, Australia
© Copyright 2025. All Rights Reserved by MedPath